): The objective of this project is to define the role of adaptor proteins in malignant transformation. Adaptor proteins are unique signaling molecules which, although devoid of any intrinsic enzymatic activity, function mainly by allowing the interconnection of other molecules in various signaling pathways through protein- protein interactions. While mutation of adaptor proteins in the laboratory can cause cells to develop malignant characteristics, a similar process appears to occur in vivo through adaptor protein interactions with various oncogenic proteins. The specific hypothesis of this project is that alteration of adaptor proteins by oncogenic tyrosine kinases is an important mechanism by which oncogenes induce malignant transformation. This project will focus on the adaptor protein CRKL which is constitutively expressed in a number of hematopoietic and non-hematopoietic cells in an unphosphorylated state. Cells which contain the BCR-ABL oncogenic tyrosine kinase, seen in all leukemic cells containing the Philadelphia-1 chromosome abnormality, express high levels of phosphorylated CRKL. The facts that CRKL binds directly to BCR-ABL, that CRKL is the most prominent tyrosine phosphorylated protein in BCR-ABL positive cells, and that significant CRKL phosphorylation occurs only in cells which express BCR-ABL are strongly suggestive that alteration of this adaptor protein through phosphorylation plays a unique role in the malignant transformation of BCR-ABL positive cells. Using several mutated forms of the CRKL protein, the specific alms of this study will be: 1) To define the role of CRKL in malignant transformation induced by BCR-ABL by determining the role of CRKL tyrosine phosphorylation in the oncogenic process and whether downstream effectors and signal transduction pathways utilized by CRKL are affected by CRKL phosphorylation; 2) To determine if CRKL in any form is transforming in the absence of BCR-ABL and develop a model of how CRKL functions with regard to its own phosphorylation; 3) To explore the role of CRKL in other solid tumor systems like lung cancer, breast cancer, and colorectal cancer which have been associated with alterations in tyrosine kinase signaling pathways.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08CA074241-03
Application #
6173540
Study Section
Subcommittee G - Education (NCI)
Program Officer
Eckstein, David J
Project Start
1998-07-01
Project End
2002-06-30
Budget Start
2000-07-11
Budget End
2001-06-30
Support Year
3
Fiscal Year
2000
Total Cost
$87,696
Indirect Cost
Name
Duke University
Department
Surgery
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Raymond, Amanda K; Beasley, Georgia M; Broadwater, Gloria et al. (2011) Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg 213:306-16
Coleman, Andrew; Augustine, Christina K; Beasley, Georgia et al. (2009) Optimizing regional infusion treatment strategies for melanoma of the extremities. Expert Rev Anticancer Ther 9:1599-609
Grubbs, Elizabeth G; Abdel-Wahab, Zeinab; Tyler, Douglas S et al. (2006) Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer. Ann Surg Oncol 13:1645-54
Abdel-Wahab, Zeinab; Cisco, Robin; Dannull, Jens et al. (2005) Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses. J Surg Res 124:264-73
Grubbs, Elizabeth G; Abdel-Wahab, Omar; Cheng, Tsung-Yen et al. (2004) In-transit melanoma: the role of alkylating-agent resistance in regional therapy. J Am Coll Surg 199:419-27
Abdel-Wahab, Omar I; Grubbs, Elizabeth; Viglianti, Benjamin L et al. (2004) The role of hyperthermia in regional alkylating agent chemotherapy. Clin Cancer Res 10:5919-29
Grubbs, Elizabeth G; Ueno, Tomio; Abdel-Wahab, Omar et al. (2004) Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery 136:210-8
Onaitis, Mark W; Kalady, Matthew F; Emani, Sirisha et al. (2003) CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy. Surgery 134:300-5
Abdel-Wahab, Zeinab; Kalady, Matthew F; Emani, Sirisha et al. (2003) Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution. Cell Immunol 224:86-97